Company news
Xenetic Biosciences, Inc. (NASDAQ:XBIO) news
Xenetic Biosciences, Inc. news releases on 6ix. Latest, Sep 16, 2026: Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement…
Press releases & updates
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
September 16, 2026
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
August 7, 2026
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
June 3, 2026
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
May 31, 2026
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
May 12, 2026
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
April 21, 2026
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
March 12, 2026
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
December 11, 2025
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
November 19, 2025
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
November 13, 2025
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
October 10, 2025
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
August 13, 2025
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
July 30, 2025
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
July 23, 2025
Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
July 8, 2025
Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreat...
July 7, 2025
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
May 14, 2025
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
April 9, 2025
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
April 8, 2025
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
March 26, 2025
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
March 25, 2025
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
March 19, 2025
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
March 18, 2025
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
March 13, 2025
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
March 12, 2025
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
February 27, 2025
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
December 15, 2024
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
December 4, 2024
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
November 20, 2024
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
November 12, 2024
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
November 11, 2024
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
November 6, 2024
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
October 21, 2024
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
October 16, 2024
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
September 10, 2024
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024
Xenetic Biosciences, Inc. Announces Executive Leadership Transition
May 21, 2024
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
May 9, 2024
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
March 21, 2024
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
January 16, 2024
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
November 9, 2023
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
October 10, 2023
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 4, 2023
Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
August 10, 2023
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
July 4, 2023
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
May 11, 2023
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
May 3, 2023
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
May 2, 2023
Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
April 10, 2023